Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aletekitug in moderate to severe ulcerative colitis
NCT07747480Phase 1Recruiting
- Sponsor
- GSK
- Start
- Sep 2026
- Primary completion
- Mar 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of aletekitug in ulcerative colitis (UC), sponsored by GSK. Primary endpoints: Adverse Events at 34 weeks, Serious Adverse Events at 34 weeks and 4 more. Started Sep 2026; status: recruiting.
02
Drugs
aletekitug
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT07747480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07747480.